ESR1 and neoplasm: A gain-of-function mutation within the FGFR3 gene in a transgenic mouse model facilitated the development of low-grade papillary bladder cancer, while ESR1 expression was significantly down-regulated, suggesting the involvement of ERα in urothelial tumorigenesis as a tumor suppressor.